4-aminopyridine is the first of the aminopyridines to be used in clinical practice. It blocks potassium channels and thereby increases acetylcholine, and possibly noradrenaline, release at nerve terminals. In man the drug has a significant action at the neuromuscular junction, but has little effect on the autonomic nervous system or muscle (smooth, skeletal, or cardiac) although such actions have been demonstrated in animals. It may be clinically useful in the reversal of nondepolariser blockade and a role in antibiotic associated block has been proposed. It may be used effectively as an analeptic agent. It appears to be a useful therapeutic agent in myasthenia gravis and Eaton Lambert syndrome, although of limited use in botulism. Its effects on the central nervous system are considerable. These account for the major side effects of the drug which include tremor, excitability and convulsions.
The aminopyridines are being extensively investigated at present. Although several monoamino and diamino derivatives of pyridine are showing promise of potential clinical value, only 4-aminopyridine (4-AP) has had much clinical use.
The pharmacological properties were initially described in 1924 by Dohrn 1 who commented on the excitatory effects on the central nervous system, as well as the vasopressor actitivity of the drug. The vasopressor effects were further evaluated in 1958 2 but it is only in the last ten to fifteen years that the actions of 4-AP at the neuromuscular junction and its effects on neurotransmitter release have been recognised and investigated. 4-AP has now been used clinically in several situations. As well as being used to reverse nondepolarising muscle relaxants, it has also been shown to have some efficacy in myasthenia gravis, Eaton Lambert syndrome and botulism. It has also been used as an analeptic agent. However, 4-AP has *M.B., Ch.B., Registrar. tF.f.A.R.A.C.S., F.F.A.R.C.S., Staff Specialist. AddrC5S: Or. N. Soni, Department of Anaesthesia, Westmcad Centre, Westmead, N.S.W. significant side effects which limit its clinical application.
The purpose of this review is to discuss the usefulness of this agent in clinical practice and to consider its various effects in terms of possible future developments III this pharmacological group.
Physicochemical Properties 4-AP belongs to a large group of monoamino and diamino derivatives of pyridine (see Figure  1 ) .
The chloride salt is water soluble, and can be prepared in solution in concentrations up to 1.0070. 3 The pKa of the compound is 9.18 and it has been shown that its potency is greater at a pH of 9.0 than 7.4. This may suggest an intracellular action, the unionised molecule being able to cross the cell membrane more readily.4
Structure Activity Relationship
The activity of the compound, with regard to potentiation of transmitter release, appears to be dependent on the pyridine ring 5 and the presence of an amino group. The 3,4-diaminopyridine in comparison to 4-AP has significantly more potent peripheral effects and Anaesthesia and Intensive Care, Vol. X, No, 2, Afay, 1982 less central nervous system activity in experimental animals, although no clinical studies are yet available in man. 4 Generally speaking the position or number of amino groups does not appear to be important, as seen by the similarity of actions of 2, 3, 4-and 3 ,4-aminopyridines. 2 However, substitution onto the amino group removes the activity of the compound.
Pharmacokinetics
Although it is now possible to measure plasma and urinary levels of 4-AP, very little pharmacokinetic data is yet available. The only study, in humans, followed the plasma levels of 4-AP after bolus intravenous administration. 6 This demonstrated a secondary peak in plasma levels between 20 and 90 minutes after injection and this precluded compartmental analysis in that study. Values for the plasma half-life and the apparent volume of distribution of the drug are not available at the present time.
The prolonged plasma decay curve did, however, suggest a large volume of distribution. No metabolites of 4-AP have been demonstrated in animals or man, and in this study up to 87070 of the administered drug was recovered, unchanged, in the urine.
Clinically, the effects of bolus intravenous administration of 0.3 mgkg-' 4-AP are detectable at S minutes, with significant reversal of neuromuscular blockade at between IS and 30 minutes. 3 No information is available on the duration of action of intravenous 4-AP, although it appears to be adequate for the 
Toxicity
The toxicity of 4-AP shows a degree of species variation, although the oral LD?O for most mammals is less than 10 mgkg -. The signs of toxicity are hypere~citabili~y, salivation, clonic and tonic convulsIOns leadmg to cardiorespiratory arrest and death. The LDSO of 4-AP for rats give? intraveno.usl~, is 8.S mgkg-' , and 20 mgkg-' If the drug IS gIven orally. However, dogs are considerably more sensitive to 4-AP, the LDSq for oral administration being 3.7 mgkg-l. I, It has been suggested that the therapeutic index of 4-A~ is in the order of 8: 1 (as compared wIth neostigmine 2: IV No long-term effects on hepatic, renal or marrow function have been demonstrated but at present it is impossible to comment on longterm toxicity in man.
Mechanisms of Action of 4-AP
4-AP has been demonstrated to act at the following sites: 1. Neuromuscular junction 4-AP has been shown to increase the release of acetycholine at the neuromuscular junction 8 -1O and a mechanism for this release has been postulated. 4-AP blocks potassium channels selectively in a variety of species."-14 It is the efflux of potassium which determines the duration of the action potential, and this is, therefore, prolonged by 4-AP. This prolonged action potential allows more calcium to move into the cell. Some authors 4 ,'5,'6 have postulated that 4-AP may act directly on calcium channels, or on voltage-dependent membrane permeability to calcium ' 7 but the actual mechanism of the calcium influx has not been fully determined. No effect on sodium channels is demonstrable. The intracellular uptake of calcium is essential for acetylcholine release '8 and the increased influx following 4-AP may result in enhanced release of acetylcholine. [15] [16] [17] 19 This may occur spontaneously, as shown by an increase in frequency of miniature end-plate potentials or following an action potential where an increased end-plate potential is seen. 8, 10, 17 No direct effect of 4-AP on the postsynaptic membrane has been demonstrated.
Central Nervous System
4-AP crosses the blood brain barrier!92! and has analeptic effects on the central nervous system. At low doses, restlessness and respiratory stimulation are seen. At higher doses, tremor and hyperexcitability develop and this leads on to frank tonic and clonic convulsive activity in experimental animals.!
The mechanism by which 4-AP causes these effects is obscure. An increase in noradrenaline turnover has been demonstrated, while that of dopamine and 5-hydroxytryptamine is unaltered. 22 It has been suggested that epileptiform activity is not related to amine turnover,! but rather is associated with a general increase in neuronal excitability. The effects of 4-AP on acetylcholine turnover in the brain have not been documented. The local application of physostigmine to the brain is associated with epileptiform activity, presumably due to the accumulation of acetylcholineY No conclusions can be drawn as to the mechanism of action of 4-AP in the central nervous system.
The respiratory stimulation associated with 4-AP administration has been investigated. Local application of 4-AP to the ventral aspect of the medulla oblongata, in experimental animals, results in increased respiratory activity.20 This may be due to enhanced acetylcholine release at the central chemoreceptors as they are cholinergic in transmission. 3 
. Spinal Cord
In the spinal cord 4-AP augments transmitter release in both excitatory and inhibitory synapses. 24 Facilitation of this nature has been described in both monosynaptic and polysynnptic spinal reflex pathways and there is, presumably, an effect on interneurone transmisstion. 25 Despite a generalised increase in neuronal activity, neither the excitatory nor inhibitory pathway predominates at low dosage, implying a degree of balanced function. 24 However, at higher doses of 4-AP convulsive activity seen may be due to intense activation of excitatory pathways.25 4. Autonomic Nervous System 4-AP increases neurotransmitter release in the autonomic nervous system. Acetylcholine release is enhanced at both ganglionic and postganglionic cholinergic synapses by 4-AP.l In rabbit vas deferens,5 rabbit ear artery,26 and rat portal vein 27 increased noradrenaline is released following exposure to 4-AP, presumably due to the action of the drug on post-ganglionic adrenergic synapses. These effects on the autonomic nervous system vary with species. In the dog, sympathetic enhancement predominates, as demonstrated by an increase in maximum rate of rise in left ventricular pressure, left ventricular systolic pressure and stroke volume. 28 In the cat, however, the cardiac responses to vagal stimulation are augmented. 28 Although a mild hypertensive effect has been documented in humans 7 several studies have commented on the absence of cardiovascular effects of 4_AP. 3 ,13,29 Overall, it would appear that 4-AP has no significant effect on the autonomic nervous system in humans, although it does have significant effects in other species.
Muscle
4-AP enhances muscle con tractility in skeletal, smooth and cardiac muscle, but with considerable species and tissue variability.
An increase in smooth muscle contractility following exposure to 4-AP can be demonstrated in rat portal vein27 and rat ileum. 2 This increase is independent of any effect on neurotransmitter release, and the mechanism by which it occurs is uncertain. No effect on human smooth muscle has yet been demonstrated.
Similarly mammalian skeletal muscle increases its contractility after administration of 4-AP as demonstrated in the rae and the cat. 30 Potassium channel blockade by 4-AP can be shown in some skeletal muscle. 14 This effect, by prolonging the action potential, may increase calcium release from the sarcoplasmic reticulum, thereby enhancing contractility.l Increased contractility may also occur in cardiac muscle. 1 Very little documentation of the direct effect of 4-AP on cardiac muscle is available and certainly the effect appears to be insignificant in man.
It is possible that an analogue of 4-AP may have clinically useful inotropic effects, but no such drug has yet been found.
In conclusion, although all three muscle types can be shown to be affected by 4-AP, this does not appear to be clinically relevant. Of interest, in this regard, although 4-AP inhibits the action of dantrolene sodium 31 it failed to trigger malignant hyperthermia in susceptible pigs.
CLINICAL USE (i) Reversal of Neuromuscular Blockade
4-AP has been used as a reversal agent for several nondepolarising muscle relaxants. A dose of 0.3 mgkg-I of 4-AP intravenously has been used to reverse the action of curare, with significant reversal at 10 minutes and full recovery by 30 minutesY Other studies suggest adequate reversal of Org NC 45 32 and pancuronium 29 can only be achieved with higher doses, 0.46 mgkg-I and 0.50 mgkg-I , respectively. Furthermore, it was noted that 0.50 mgkg-I of 4-AP resulted in significantly less antagonism of pancuronium than a 22 J.lgkg-I dose of neostigmine. At this dosage, however, side effects such as restlessness and confusion may occur and their incidence increases with increasing dosage.
One postulated advantage of 4-AP over anticholinesterase drugs is its lack of muscarinic effects, and therefore the avoidance of atropine. 29 It has been shown that synergism occurs with neostigmine and 4-AP thereby allowing a reduction in the dose of neostigmine required for reversal, and consequently less atropine is needed. 29 ,32 0.3 mgkg-1 4-AP given with 7 J.lgkg -1 neostigmine will achieve the same degree of antagonism as 22 J.lgkg -1 neostigmine on its own. A 60 to 70 per cent reduction in atropine requirement is therefore possible.
Several antibiotics are known to prolong neuromuscular blockade when given with nondepolarising relaxantsY Gentamicin and other aminoglycosides have a predominantly presynaptic effece 4 while polymyxin B, lincomycin and clindamycin have a curare-like effect. 15 Both groups may be reversed with 4-AP although in one study no advantage over neostigmine was demonstrated. 33 anaesthetic using dosages of 0.3 mgkg-I of 4-AP, intravenously. 19 As with most analeptic agents, restlessness on emergence is a characteristic feature. This is also seen when it is used to reverse respiratory depression. As previously mentioned 20 4-AP probably acts on the cholinergic central chemoreceptors to stimulate respiration. Fentanyl-induced respiratory depression may be reversed by 4-AP, as assessed by improvement in tidal volume and respiratory rate. 36 However, the analgesic properties of opiates are not affected and this may be an advantage in the postoperative recovery period. Respiratory depression from inhalation of agents such as halothane may also be reversed. 7 (iii) In Myasthenia Gravis and Eaton Lambert Syndrome Myasthenia gravis is a postsynaptic condition with a functional reduction in acetylcholine receptors, while Eaton Lambert syndrome is a consequence of impaired acetylcholine release. Anticholinesterases are the mainstay of treatment in the former group but are of less benefit in the latter syndrome. 4-AP has been used both intravenously and orally in the treatment of myasthenis gravis. 21 ,37 Intravenous doses of 20 mg and oral doses of between 20 and 100 mg daily have been used, with and without anticholinesterases. The dosage in mgkg -1 was not stated in these papers. Significant therapeutic benefit was achieved, but side effects, predominantly fitting, limited its usefulness. Similarly the drug has been used in Eaton Lambert syndrome. 21 ,38,39 Following an oral dose of 4-AP, maximum benefit is attained at between 45 and 90 minutes with improvement in muscle power lasting in excess of 180 minutes. The dosage is of the order of 40 mg to 100 mg daily in four divided doses. In these patients the drug has been used for up to 10 months with considerable therpeutic benefit. At the higher doses, 1.7-3.5 mgkg-I per day orally, side effects such as fitting and acute confusional states have been noted. 21 Tolerance has been documented in the long term use of 4-AP.
(iv) In Botulism
Botulism is a condition caused by potent neurotoxins which block the presynaptic nerve terminals, thereby inhibiting acetylcholine release. In patients treated with 4-AP an improvement in muscle power resulted. 40 ,4! This improvement, however, was transient and did not significantly affect the respiratory muscles. This transient improvement seen with bolus intravenous doses of 0.5 mgkg-! could be sustained if an infusion rate of 0.25 mgkg-! per hour was used after the initial bolus of 0.5 mgkg-! was given prior to infusion. However, both patients treated with the infusion developed convulsions. Overall 4-AP appears to be of little value as the doses required to produce therapeutic benefit are unacceptable in view of the side effects caused.
(v) In Demyelinating Disease
One study has suggested an improvement in transmission in demyelinated motor nerves following 4-AP. This may prove to be of value in demyelinating conditions, such as multiple sclerosis.42
Side Effects of 4-AP
The side effects of 4-AP are predominantly on the central nervous system. We shall consider these as they occur with increasing dosage and then discuss other side effects.
At low doses, 0.2 to 0.5 mgkg-! intravenously, side effects are uncommon. In myasthenic patients given this dose, some complained of unsteadiness on their feet, although no objective signs of disturbance of gait or co-ordination could be elicited. 37 Higher doses, 0.5 mgkg-! to 1.0 mgkg-! intravenously are associated with restlessness or anxiety in occasional patients. 4-AP given intravenously in doses in excess of 1.0 mgkg-! may produce tremor, restlessness and hyperexcitability. This may proceed to tonic and clonic convulsions! and in higher doses grand mal fits ensue. Documented infusion regimes, as previously mentioned, are also associated with fitting. Diazepam has been found effective in managing these fits.4! In neurological practice oral administration has been used. Oral doses of 1.0 to 1.5 mgkg-! per day are associated with restlessness, anxiety and inability to sleep. One patient complained of light sensitivity, but neuropthalmological examination was normal. 38 In the dose range 1. 7 to 3.5 mgkg -! per day acute confusional states sometimes occur which resolve on cessation of the drug. The development of seizures does, however, become a problem. As patients appear to develop tolerance 2 ! to oral 4-AP necessitating gradual increases in dosage, doses are fairly readily reached at which epileptiform activity may be anticipated.
Following intravenous administration of 4-AP many patients develop perioral paraesthesia within a few seconds 37 which usually disappears after a few minutes. Pain on injection may be a problem and a few patients have developed a deep aching pain in the same arm which persists for several hours. 37 No information is yet available regarding the long-term side effects of 4-AP. In patients who have been on the drug for several months, no hepatic, renal, or marrow damage has been documented. 21 The side-effects of this drug are obviously considerable and with increased usage it will be interesting to see the incidence of these effects within therapeutic dosage limits. CONCLUSION 4-AP is a new drug in the anaesthetic armanentarium. While its mode of action is of considerable interest and its spectrum of clinical uses quite broad, its side-effects preclude its enthusiastic reception as a reversal agent. However, its potential use as an atropine-sparing adj unct to conventional reversal agents may be of value, as are some of its other properties. The use of 4-AP in myasthenic patients undergoing anaesthesia may be of benefit in the postoperative period, as well as in their long term management.
As an analeptic agent its advantages may be offset by the restlessness and anxiety it may cause. Its lack of analgesic reversal could prove of use in the recovery room or in intensive care situations, though again its side effects limit its usefulness.
As a group the aminopyridines would appear to have tremendous potential. 3,4-diaminopyridine is said to have considerably more potent peripheral effects with less central nervous system activity. Other derivatives may prove to have more marked cardiovascular or neuromuscular efficiency with fewer toxicity problems. However, at the present time, on the limited data available, it would appear that 4-AP, although an interesting agent, will prove to have limited clinical application.
